Adalimumab and infliximab were the most common biologic therapies associated with the onset of palmoplantar pustulosis and palmoplantar pustular psoriasis.
Use of biologic therapies such as adalimumab and infliximab may increase the risk of developing palmoplantar pustulosis (PPP) and palmoplantar pustular psoriasis (PPPP), according to study findings published in International Journal of Dermatology.
As 2 chronic inflammatory skin conditions characterized by eruptions of sterile pustules on the palms and/or soles, PPP and PPPP development has been linked with several risk factors, including smoking, emotional stress, and certain drugs, such as tumor necrosis factor-α (TNF-α) inhibitors.
Although various case reports and case series have detailed the use of biologic treatments such as TNF-α inhibitors (eg, infliximab and adalimumab) to treat PPP, the researchers of the present study note they have also been associated with paradoxical PPP and PPPP onset following biologic therapy.
“Currently, it is unclear which specific biologics are associated with the onset of PPP or PPPP,” they added. “To our knowledge, there is no existing review that summarizes reports of PPP or PPPP onset following biologic therapy.”
They conducted a systematic review of the MEDLINE and Embase databases for articles that reported the clinical features and outcomes of patients with PPP or PPPP associated with the initiation of biologic therapy. Using the term palmoplantar pustulosis and variations of biologics and generic names in the review conducted on September 2, 2020, the researchers also assessed for recommendations on the most successful methods of achieving complete or partial remission of PPP/PPPP.
Of the 383 articles identified by the systematic review, 53 articles including 155 patients with biologic-associated PPP and PPPP met inclusion criteria (mean age, 44.1 years; 71.6% female). The most common indications for biologic use were rheumatoid arthritis (n = 32), ankylosing spondylitis (n = 26), psoriasis or psoriatic arthritis (n = 18), Crohn's disease (n = 15), and inflammatory bowel disease (n = 11).
In their findings, the most common biologics associated with PPP or PPPP were the TNF-α inhibitors adalimumab (43.9%) and infliximab (33.3%), followed by etanercept (4.5%) and certolizumab (4.5%). Interleukin-17 inhibitors, such as secukinumab (7.6%) and brodalumab (1.5%), were reported only in association with PPPP.
Regarding remission of PPP/PPPP, 58.8% of patients reported complete remission in 3.6 months, 23.5% had partial remission in 3.7 months, 11.8% had no resolution, and 5.9% had aggravation with their treatments. The most common treatments that led to complete response were biologic switching (n = 8) and topical corticosteroids (n = 16), including clobetasol propionate cream 0.05% and halobetasol 0.05% ointment.
“Clinicians should anticipate PPP or PPPP as potential drug reactions to biologics such as adalimumab and infliximab,” concluded the study authors. “Large-scale studies are required to confirm our findings and further explore the pathogenesis for biologic-associated PPP and PPPP.”
Reference
Lu JD, Lytvyn Y, Mufti A, et al. Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review. Int J Dermatol. Published online February 6, 2022. doi:10.1111/ijd.16064
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More